Houston-based Procyrion evaluated Aortix percutaneous mechanical circulatory support (pMCS) pump in patients with acute decompensated heart failure (ADHF) and worsening renal function. This is known as cardiorenal syndrome (CRS).
The pump patients — unresponsive to available medical therapy — demonstrated significant improvements across a range of functions. These include kidney function, cardiac function and patient-reported assessment of shortness of breath at 30 days.
Procyrion presented results today at the Technology and Heart Failure Therapeutics (THT) conference in Boston.
Dr. Jennifer A. Cowger, section head of heart transplantation and mechanical circulatory support, Henry Ford Hospital in Detroit, said patients with CRS often end up the most difficult to …